MY ACCOUNT | NEWSLETTER |

Embark pinpoints deafness gene in RRs


Dog genetic company, Embark Veterinary, Inc., has identified a mutation associated with deafness in certain dogs. The gene, EPS8L2, when mutated can lead to early-onset of deafness in Rhodesian Ridgeback dogs. 

Dogs with the gene are at increased risk of the disease, which can strike as early as 1 or 2 years old, or as little as 4 months old in purebred canines. Knowing which dogs are at risk and can be managed is helpful in the hunting and sport breed, according to the company. Dogs at risk can be trained visually and adjust by learning from other dogs, according to breeders. The research came about as a collaboration between breeders, pet owners, and scientists at Embark. 

"The single constant in the decade-long search for this mutation has been the dedicated breeders who painstakingly worked with their puppy owners to provide the samples that made this discovery possible," said Denise Flaim, former co-chair of the Rhodesian Ridgeback Club of the United States Health and Genetics Committee. "This is a long-awaited tool for Ridgeback breeders, but it should be used wisely. Now we can identify carriers, which can be bred safely to non-carriers, to maintain genetic diversity and confidently produce hearing offspring." The recessive gene needs to be present in both parents as carriers to appear in puppies.

Flaim initially reached out to Dr. Mark Neff, senior director of scientific discovery at Embark about collaborating. Neff, who works at the UC Davis Veterinary Genetics Lab had linked canine chromosome 18 and early-onset deafness in 2009. Once the researchers teamed with the Rhodesian Ridgeback Club, they coordinated a study along with projectDOG, a nonprofit, and analyzed genetic markers for the disease. DNA genotyping allowed the team to identify the deleted gene linked to the disease. 

"When we founded Embark in 2015, we did so to get to the root of genetic health disorders in dogs," said Ryan Boyko, chief executive officer of Embark. "This first health discovery is a significant accomplishment by our science team and is the first step toward the world Embark is creating – one where genetics enhances dogs' lives instead of detracting from them. By informing Rhodesian Ridgeback breeders about this genetic mutation in their potential breeding pairs, we can virtually eliminate this condition in Ridgebacks via genetic screening."


Like1
Dislike0
  • Please enter a comment


Name *
Email address *
Comment *


* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.


I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies



More news

Manoeuvring the innovative drug delivery systems for veterinary therapeutics: Present day demand

Like0
Dislike0

Stereotactic Radiation Therapy Planning, Dose Prescription and Delivery in Veterinary Medicine: A Systematic Review on Completeness of Reporting and Proposed Reporting Items

Like0
Dislike0

Management and medicine of backyard poultry

Like0
Dislike0

Horse makes immediate recovery following removal of large nasal mass

Like0
Dislike0

Zoetis Receives Conditional Approval for Dectomax®-CA1 Injectable for the Prevention and Treatment of New World Screwworm Myiasis in Cattle

Like0
Dislike0

Newsletter

 
 

News of interest

EVENTS

Copyright © 2025 - All Rights Reserved
ISSN 2768-198X

Top